Cited by 4,427Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesHematopoietic Stem Cell Transplantation

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

Open access

Greenberg, Peter, Cox, Christopher, LeBeau, Michelle M., Fenaux, Pierre, Morel, Pierre, Sanz, Guillermo, Sanz, Miguel, Vallespi, Teresa, Hamblin, Terry, Oscier, David, Ohyashiki, Kazuma, Toyama, Keisuke, Aul, Carlo, Mufti, Ghulam, Bennett, John·1997·Blood

DOI 10.1182/blood.v89.6.2079

Open this paper in CoChat — free account Open PDF

Abstract

Despite multiple disparate prognostic risk analysis systems for evaluating clinical outcome for patients with myelodysplastic syndrome (MDS), imprecision persists with such analyses. To attempt to improve on these systems, an International MDS Risk Analysis Workshop combined cytogenetic, morphological, and clinical data from seven large previously reported risk-based studies that had generated prognostic systems. A global analysis was performed on these patients, and critical prognostic variables were re-evaluated to generate a consensus prognostic system, particularly using a more refined bone marrow (BM) cytogenetic classification. Univariate analysis indicated that the major variables having an impact on disease outcome for evolution to acute myeloid leukemia were cytogenetic abnormalities, percentage of BM myeloblasts, and number of cytopenias; for survival, in addition to the above, variables also included age and gender. Cytogenetic subgroups of outcome were as follows: “good” outcomes were normal, −Y alone, del(5q) alone, del(20q) alone; “poor” outcomes were complex (ie, ≥3 abnormalities) or chromosome 7 anomalies; and “intermediate” outcomes were other abnormalities. Multivariate analysis combined these cytogenetic subgroups with percentage of BM blasts and number of cytopenias to generate a prognostic model. Weighting these variables by their statistical power separated patients into distinctive subgroups of risk for 25% of patients to undergo evolution to acute myeloid leukemia, with: low (31% of patients), 9.4 years; intermediate-1 (INT-1; 39%), 3.3 years; INT-2 (22%), 1.1 years; and high (8%), 0.2 year. These features also separated patients into similar distinctive risk groups for median survival: low, 5.7 years; INT-1, 3.5 years; INT-2, 1.2 years; and high, 0.4 year. Stratification for age further improved analysis of survival. Compared with prior risk-based classifications, this International Prognostic Scoring System provides an improved method for evaluating prognosis in MDS. This classification system should prove useful for more precise design and analysis of therapeutic trials in this disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood.v89.6.2079

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

International System for Human Cytogenetic Nomenclature
National Cancer Institute (2020) · Definitions · doi:10.32388/78qroa · Cited by 6,831
Proposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,619
Self-citation
Myelodysplastic syndromes: a scoring system with prognostic significance
Mufti, G. J., Stevens, J. R., Oscier, D. G., Hamblin, T. J., & Machin, D. (1985) · British Journal of Haematology · doi:10.1111/j.1365-2141.1985.tb07329.x · Cited by 507
Self-citation
The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., Sultan, C., & Cox, C. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb06734.x · Cited by 431
Self-citation
Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients
Sanz, G. F., Sanz, M. Á., Vallespı́, T., Cañizo, M., Torrabadella, M., Garcia, S., Irriguible, D., & Miguel, J. F. S. (1989) · Blood · doi:10.1182/blood.v74.1.395.395 · Cited by 406
Self-citation
The 5q− anomaly
BERGHE, H. V. D., Vermaelen, K., Mecucci, C., Barbieri, D., & Tricot, G. J. K. (1985) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(85)90016-0 · Cited by 322
Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
Morel, P., Hebbar, M., Laï, J. L., Duhamel, A., Preudhomme, C., Wattel, E., Bauters, F., & Fenaux, P. (1993) · PubMed · Cited by 300
Self-citation
Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
Aul, C., Gattermann, N., Heyll, A., Germing, U., Derigs, G., & Schneider, W. (1992) · PubMed · Cited by 265
Self-citation
Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes
Rh, J., Cornbleet, M., Vardiman, J., Larson, R. A., Beau, M. M. L., & Rowley, J. (1986) · Blood · doi:10.1182/blood.v67.6.1765.1765 · Cited by 246
Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia
Yunis, J. J., Lobell, M., Arnesen, M. A., Oken, M. M., Mayer, M. G., Rydell, R. E., & Brunning, R. D. (1988) · British Journal of Haematology · doi:10.1111/j.1365-2141.1988.tb06188.x · Cited by 232

Show all 33 references

Sorted by citations

Items 101–200 of 1,003

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
Kosmider, O., Gelsi‐Boyer, V., Cheok, M. H.-C., Grabar, S., Della-Valle, V., Picard, F., Viguié, F., Quesnel, B., Beyne‐Rauzy, O., Solary, É., et al. (2009) · Blood · doi:10.1182/blood-2009-04-215814 · Cited by 285
Self-citation
Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
Jabbour, E. J., Garcia‐Manero, G., Batty, N., Shan, J., O'Brien, S. M., Cortes, J. E., Ravandi, F., Issa, J. J., & Kantarjian, H. M. (2010) · Cancer · doi:10.1002/cncr.25247 · Cited by 276
Prognostic Significance ofASXL1Mutations in Patients With Myelodysplastic Syndromes
Thol, F. R., Friesen, I., Damm, F., Yun, H., Weissinger, E. M., Krauter, J., Wagner, K., Chaturvedi, A., Sharma, A., Wichmann, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4938 · Cited by 278
Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy
Sloand, E. M., Wu, C. O., Greenberg, P. L., Young, N. S., & Barrett, J. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9214 · Cited by 272
Self-citation
HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome
Saunthararajah, Y., Nakamura, R., Nam, J., Robyn, J. A., Loberiza, F. R., Maciejewski, J. P., Simonis, T. B., Molldrem, J. J., Young, N. S., & Barrett, A. J. (2002) · Blood · doi:10.1182/blood.v100.5.1570.h81702001570_1570_1574 · Cited by 272
Angiogenesis in myelodysplastic syndromes
Pruneri, G., Bertolini, F., Soligo, D. A., Carboni, N., Cortelezzi, A., Ferrucci, P. F., Buffa, R., Lambertenghi‐Deliliers, G., & Pezzella, F. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6693515 · Cited by 268
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes
Sallman, D. A., & List, A. (2019) · Blood · doi:10.1182/blood-2018-10-844654 · Cited by 273
Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia.
Sierra, J., Pérez, W. S., Rozmán, C., Carreras, E., Klein, J. P., Rizzo, J. D., Davies, S. M., Lazarus, H. M., Bredeson, C., Marks, D. I., et al. (2002) · PubMed · Cited by 269
Cytogenetic risk stratification in chronic myelomonocytic leukemia
Such, E., Cervera, J., Costa, D., Solé, F. G., Vallespı́, T., Luño, E., Collado, R., Calasanz, M. J., Hernández‐Rivas, J. M., Cigudosa, J. C., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.030957 · Cited by 269
Self-citation
Hypermethylation of the p15INK4B Gene in Myelodysplastic Syndromes
Uchida, T., Kinoshita, T., Nagai, H., Nakahara, Y., Saito, H., Hotta, T., & Murate, T. (1997) · Blood · doi:10.1182/blood.v90.4.1403 · Cited by 265
Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes
Solé, F. G., Espinet, B., Calasanz, M. J., Cervera, C., Calasanz, Luño, Prieto, Granada, I., Hernández, Cigudosa, et al. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.01868.x · Cited by 266
One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
Tefferi, A., Lasho, T. L., Jimma, T., Finke, C. M., Gangat, N., Vaidya, R., Begna, K. H., Al‐Kali, A., Ketterling, R. P., Hanson, C. A., et al. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2011.11.001 · Cited by 260
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
for the International Working Group for MDS Molecular Prognostic Committee, Haase, D., Stevenson, K. E., Neuberg, D., Maciejewski, J. P., Nazha, A., Sekeres, M. A., Ebert, B. L., Garcia-Manero, G., Haferlach, C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0351-2 · Cited by 259
Self-citation
Diagnosis and Treatment of Myelodysplastic Syndromes
Sekeres, M. A., & Taylor, J. (2022) · JAMA · doi:10.1001/jama.2022.14578 · Cited by 267
Somatic SETBP1 mutations in myeloid malignancies
Makishima, H., Yoshida, K., Nguyen, N., Przychodzen, B. P., Sanada, M., Okuno, Y., Ng, K. P., Gudmundsson, K. O., Vishwakarma, B. A., Jerez, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2696 · Cited by 262
Clinical Relevance of Bone Marrow Fibrosis and CD34-Positive Cell Clusters in Primary Myelodysplastic Syndromes
Porta, M. G. D., Malcovati, L., Boveri, E., Travaglino, E., Pietra, D., Pascutto, C., Passamonti, F., Invernizzi, R., CASTELLO, A., Magrini, U., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2246 · Cited by 255
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid
Kuendgen, A., Strupp, C., Aivado, M. A., Bernhardt, A., Hildebrandt, B., Haas, R. R., Germing, U., & Gattermann, N. (2004) · Blood · doi:10.1182/blood-2003-12-4333 · Cited by 257
Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
Garcia‐Manero, G., Gore, S. D., Cogle, C. R., Ward, R., Shi, T., MacBeth, K. J., Laille, E. J., Giordano, H., Sakoian, S., Jabbour, E. J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4226 · Cited by 253
The incidence and impact of thrombocytopenia in myelodysplastic syndromes
Kantarjian, H. M., Giles, F. J., List, A. F., Lyons, R. M., Sekeres, M. A., Pierce, S. A., Deuson, R. R., & Leveque, J. A. (2007) · Cancer · doi:10.1002/cncr.22602 · Cited by 251
Haematopoietic stem cell transplantation for patients with myelo‐dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
de Witte, T., Hermans, J., Vossen, J. M. J. J., Bacigalupo, A. P., Meloni, G., Jacobsen, N. O., Ruutu, T., Ljungman, P. T., Gratwohl, A. A., Runde, V., et al. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02200.x · Cited by 250
Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia
Maciejewski, J. P., Risitano, A. M., Sloand, E. M., Núñez, O., & Young, N. S. (2002) · Blood · doi:10.1182/blood.v99.9.3129 · Cited by 249
Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys
Sekeres, M. A., Schoonen, W. M., Kantarjian, H., List, A., Fryzek, J., Paquette, R., & Maciejewski, J. P. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn349 · Cited by 248
Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
Prébet, T., Sun, Z., Figueroa, M. E., Ketterling, R. P., Melnick, A. M., Greenberg, P. L., Herman, J. G., Juckett, M., Wang, E. S., Smith, M. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.3102 · Cited by 247
Self-citation
The Myelodysplastic Syndromes: Diagnosis and Treatment
Steensma, D. P., & Bennett, J. M. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.1.104 · Cited by 242
Self-citation
Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation
Pedersen-Bjergaard, J., Andersen, M. K., & Christiansen, D. H. (2000) · Blood · doi:10.1182/blood.v95.11.3273 · Cited by 244
Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia
Pedersen-Bjergaard, J., Andersen, M. K., Christiansen, D. H., & Nerlov, C. (2002) · Blood · doi:10.1182/blood.v99.6.1909 · Cited by 243
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome
Porta, M. G. D., Malcovati, L., Strupp, C., Ambaglio, I., Kuendgen, A., Zipperer, E., Travaglino, E., Invernizzi, R., Pascutto, C., Lazzarino, M., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.033506 · Cited by 243
Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level
Nilsson, L., Åstrand‐Grundström, I., Arvidsson, I., Jacobsson, B., Hellström‐Lindberg, E., Hast, R., & Jacobsen, S. E. W. (2000) · Blood · doi:10.1182/blood.v96.6.2012 · Cited by 241
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations
Will, B., Zhou, L., Vogler, T. O., Ben-Neriah, S., Schinke, C., Tamari, R., Yu, Y., Bhagat, T. D., Bhattacharyya, S., Barreyro, L., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399683 · Cited by 240
Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study
MEKINIAN, A., Grignano, É., Braun, T., Decaux, O., Liozon, É., Costedoat-Chalumeau, N., Kahn, J., Hamidou, M., Park, S., Puéchal, X., et al. (2015) · Lara D. Veeken · doi:10.1093/rheumatology/kev294 · Cited by 238
Self-citation
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes
van de Loosdrecht, A. A., Alhan, C., Béné, M. C., Porta, M. G. D., Dräger, A. M., Feuillard, J., Font, P., Germing, U., Haase, D. T., Homburg, C., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.005801 · Cited by 238
Self-citation
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes
Gerstung, M., Pellagatti, A., Malcovati, L., Giagounidis, A. A. N., Porta, M. G. D., Jädersten, M., Dolatshad, H., Verma, A. K., Cross, N. C. P., Vyas, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms6901 · Cited by 237
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
Sekeres, M. A., Othus, M., List, A. F., Odenike, O., Stone, R. M., Gore, S. D., Litzow, M. R., Buckstein, R., Fang, M., Roulston, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.2510 · Cited by 237
Epidemiology of Myelodysplastic Syndromes
Ma, X. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.04.014 · Cited by 237
Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999
Cripe, L. D., Uno, H., Paietta, E. M., Litzow, M. R., Ketterling, R. P., Bennett, J. M., Rowe, J. M., Lazarus, H. M., Luger, S. M., & Tallman, M. S. (2010) · Blood · doi:10.1182/blood-2010-04-277269 · Cited by 236
Self-citation
Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis
Scott, B. L., Sandmaier, B. M., Storer, B. E., Maris, M. B., Sorror, M. L., Maloney, D. G., Chauncey, T. R., Storb, R. F., & Deeg, H. J. (2005) · Leukemia · doi:10.1038/sj.leu.2404010 · Cited by 235
Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow
Hofmann, W., de Vos, S., Komor, M., Hoelzer, D. F., Wachsman, W., & Koeffler, H. P. (2002) · Blood · doi:10.1182/blood.v100.10.3553 · Cited by 235
Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients
Estey, E. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2731 · Cited by 238
Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)
Greenberg, P. L., Lee, S. J., Advani, R. H., Tallman, M. S., Sikic, B. I., Letendre, L., Dugan, K., Lum, B. L., Chin, D. L., Dewald, G. W., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.048 · Cited by 234
Self-citation
Myelodysplastic and Myeloproliferative Disorders of Childhood: A Study of 167 Patients
Luna‐Fineman, S., Shannon, K., Atwater, S. K., Davis, J. H., Masterson, M., Ortega, J. A., Sanders, J. E., Steinherz, P. G., Weinberg, V., & Lange, B. J. (1999) · Blood · doi:10.1182/blood.v93.2.459 · Cited by 234
A role for tumour necrosis factor‐α, Fas and Fas‐Ligand in marrow failure associated with myelodysplastic syndrome
Gersuk, G. M., Beckham, C., Loken, M. R., Kiener, P. A., Anderson, J. E., Farrand, A. L., Troutt, A. B., Ledbetter, J. A., & Deeg, J. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00933.x · Cited by 232
The fundamental role of epigenetics in hematopoietic malignancies
Galm, O., Herman, J. G., & Baylin, S. B. (2005) · Blood Reviews · doi:10.1016/j.blre.2005.01.006 · Cited by 230
Genetics of therapy-related myelodysplasia and acute myeloid leukemia
Pedersen-Bjergaard, J., Andersen, M. K., Andersen, M. T., & Christiansen, D. H. (2008) · Leukemia · doi:10.1038/sj.leu.2405078 · Cited by 230
Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies
Sanz, G. F., Saavedra, S., Planelles, D., Senent, L., Cervera, J., Barragán, E., Jiménez, C., Larrea, L., Martı́n, G., Martı́nez, J., et al. (2001) · Blood · doi:10.1182/blood.v98.8.2332 · Cited by 230
Self-citation
Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival
Valcárcel, D., Martino, R., Caballero, D. M., Martín, J., Ferra, C. M., Nieto, J. B., Sampol, A., Bernal, T., Piñana, J. L., Vázquez, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.1641 · Cited by 229
Effect of Diagnosis (Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, or Acute Myeloid Leukemia [AML]) on Outcome of AML-Type Chemotherapy
Estey, E. H., Thall, P. F., Beran, M., Kantarjian, H. M., Pierce, S. A., & Keating, M. J. (1997) · Blood · doi:10.1182/blood.v90.8.2969 · Cited by 229
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
Schroeder, T. A., Czibere, A. G., Platzbecker, U., Bug, G., Uharek, L., Luft, T., Giagounidis, A. A. N., Zohren, F., Bruns, I., Wolschke, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.7 · Cited by 226
Cytogenetic features in myelodysplastic syndromes
Haase, D. T. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0483-y · Cited by 227
Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes
Molldrem, J. J., Leifer, E., Bahceci, E., Saunthararajah, Y., Rivera, M., Dunbar, C. E., Liu, J., Nakamura, R., Young, N. S., & Barrett, A. J. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-3-200208060-00007 · Cited by 226
Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program
Castro-Malaspina, H. R., Harris, R. E., Gajewski, J., Ramsay, N. K. C., Collins, R. H., Dharan, B., King, R., & Deeg, H. J. (2002) · Blood · doi:10.1182/blood.v99.6.1943 · Cited by 226
Identification of distinct prognostic subgroups in low- and intermediate-1–risk myelodysplastic syndromes by flow cytometry
van de Loosdrecht, A. A., Westers, T. M., Westra, A. H., Dräger, A. M., van der Velden, V. H. J., & Ossenkoppele, G. J. (2007) · Blood · doi:10.1182/blood-2007-07-098764 · Cited by 225
Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value
Smith, A., Mohamedali, A. M., Kulasekararaj, A. G., Lim, Z., Gäken, J. A., Lea, N. C., Przychodzen, B. P., Mian, S. A., Nasser, E. E., Shooter, C. C., et al. (2010) · Blood · doi:10.1182/blood-2010-03-274704 · Cited by 236
Self-citation
Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine
Lübbert, M., Wijermans, P., Kunzmann, R., Verhoef, G. E. G., Bosly, A., Ravoet, C., André, M. P. E., & Ferrant, A. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02933.x · Cited by 224
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
Oran, B., Lima, M. J. G. D., Garcia‐Manero, G., Thall, P. F., Lin, R., Popat, U., Alousi, A. M., Hosing, C. M., Giralt, S. A., Rondón, G., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002544 · Cited by 222
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management
Garcia‐Manero, G. (2023) · American Journal of Hematology · doi:10.1002/ajh.26984 · Cited by 241
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders
Damm, F., Chesnais, V., Nagata, Y., Yoshida, K., Scourzic, L., Okuno, Y., Itzykson, R., Sanada, M., Shiraishi, Y., Gelsi‐Boyer, V., et al. (2013) · Blood · doi:10.1182/blood-2012-11-469619 · Cited by 226
Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes
Patnaik, M. M., Padron, E., Laborde, R. R., Lasho, T. L., Finke, C. M., Hanson, C. A., Hodnefield, J. M., Knudson, R. A., Ketterling, R. P., Al‐Kali, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.88 · Cited by 222
Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
Solé, F. G., Luño, E., Sanzo, C., Espinet, B., Sanz, G. F., Cervera, J., Calasanz, M. J., Cigudosa, J. C., Millá, F., Ribera, J., et al. (2005) · PubMed · Cited by 216
Self-citation
Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome
Deschler-Baier, B., Ihorst, G., Platzbecker, U., Germing, U., März, E., de Figuerido, M., Fritzsche, K., Haas, P. S., Salih, H. R., Giagounidis, A. A. N., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.067892 · Cited by 214
Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype
Pellagatti, A. (2006) · Blood · doi:10.1182/blood-2005-12-4769 · Cited by 209
Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia
Litzow, M. R., Tarima, S. S., Pérez, W. S., Bolwell, B. J., Cairo, M. S., Camitta, B. M., Cutler, C. S., Lima, M. J. G. D., DiPersio, J. F., Gale, R. P., et al. (2009) · Blood · doi:10.1182/blood-2009-10-249128 · Cited by 213
Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management
Bravo, G. M., & Garcia‐Manero, G. (2017) · American Journal of Hematology · doi:10.1002/ajh.24930 · Cited by 212
Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31
Giagounidis, A. A. N., Germing, U., Haase, S. P., Hildebrandt, B., Schlegelberger, B., Schoch, C., Wilkens, L., Heinsch, M., Willems, H. P. J., Aivado, M. A., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403189 · Cited by 210
Self-citation
Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.
Szpurka, H., Tiu, R., Murugesan, G., Aboudola, S., Hsi, E., Theil, K., Sekeres, M., & Maciejewski, J. (2006) · Blood · doi:10.1182/blood-2006-02-005751 · Cited by 199
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms
Wang, S. A., Hasserjian, R. P., Fox, P. S., Rogers, H. J., Geyer, J. T., Chabot‐Richards, D., Weinzierl, E. P., Hatem, J., Jaso, J. M., Kanagal‐Shamanna, R., et al. (2014) · Blood · doi:10.1182/blood-2014-02-553800 · Cited by 205
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Greenberg, P. L., Sun, Z., Miller, K. B., Bennett, J. M., Tallman, M. S., Dewald, G. W., Paietta, E. M., van der Jagt, R., Houston, J. G., Thomas, M. L., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211797 · Cited by 203
Self-citation
Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies
Damaj, G. L., Duhamel, A., Robin, M., Beguin, Y. P., Michallet, M., Mohty, M., Vigouroux, S., Bories, P., Garnier, A., Cheikh, J. E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.3499 · Cited by 206
The myelodysplastic syndrome.
Galton, D. A. G. (1989) · BMJ · doi:10.1136/bmj.299.6699.582 · Cited by 207
Allogeneic Bone Marrow Transplantation for Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Long-Term Study of 70 Patients—Report of the French Society of Bone Marrow Transplantation
Yakoub‐Agha, I., Salmonière, P. D. L., Ribaud, P., Sutton, L., Wattel, E., Kuentz, M., Jouet, J. P., Marit, G., Milpied, N. J., Deconinck, É., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.963 · Cited by 205
Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?
Barrett, J., Saunthararajah, Y., & Molldrem, J. (2000) · Seminars in Hematology · doi:10.1016/s0037-1963(00)90027-1 · Cited by 207
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS
Kanakry, C. G., Tsai, H., Bolaños‐Meade, J., Smith, B. D., Gojo, I., Kanakry, J. A., Kasamon, Y. L., Gladstone, D. E., Matsui, W. H., Borrello, I., et al. (2014) · Blood · doi:10.1182/blood-2014-07-587477 · Cited by 204
Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF
Jädersten, M., Montgomery, S., Dybedal, I., Porwit‐MacDonald, A., & Hellström-Lindberg, E. (2005) · Blood · doi:10.1182/blood-2004-10-3872 · Cited by 203
Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning
Ho, A. Y. L., Pagliuca, A., Kenyon, M., Parker, J. E., Mijović, A., Devereux, S., & Mufti, G. J. (2004) · Blood · doi:10.1182/blood-2003-12-4207 · Cited by 203
Self-citation
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells
Bornhäuser, M., Storer, B. E., Slattery, J. T., Appelbaum, F. R., Deeg, H. J., Hansen, J. A., Martin, P. J., McDonald, G. B., Nichols, W. G., Radich, J. P., et al. (2003) · Blood · doi:10.1182/blood-2002-11-3567 · Cited by 203
Interferon-γ and tumor necrosis factor-α induce an immunoinhibitory molecule, B7-H1, via nuclear factor-κB activation in blasts in myelodysplastic syndromes
Kondo, A., Yamashita, T., Tamura, H., Zhao, W., Tsuji, T., Shimizu, M., Shinya, E., Takahashi, H., Tamada, K., Chen, L., et al. (2010) · Blood · doi:10.1182/blood-2009-12-255125 · Cited by 201
The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia
Barosi, G., Ambrosetti, A., Finelli, C., Grossi, A., Leoni, P., Liberato, N. L., Petti, M. C., Pogliani, E., Ricetti, M., Rupoli, S., et al. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01262.x · Cited by 201
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome
Rhyasen, G. W., Bolanos, L., Fang, J., Jerez, A., Wunderlich, M., Rigolino, C., Mathews, L., Ferrer, M., Southall, N., Guha, R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.006 · Cited by 199
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status
Schnittger, S., Haferlach, C., Ulke, M., Alpermann, T., Kern, W., & Haferlach, T. (2010) · Blood · doi:10.1182/blood-2010-02-267955 · Cited by 207
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults
Savona, M. R., Malcovati, L., Komrokji, R. S., Tiu, R. V., Mughal, T. I., Orazi, A., Kiladjian, J., Padron, E., Solary, É., Tibes, R., et al. (2015) · Blood · doi:10.1182/blood-2014-10-607341 · Cited by 202
Self-citation
Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
Kantarjian, H. M., Fenaux, P., Sekeres, M. A., Becker, P. S., Boruchov, A. M., Bowen, D., Hellström‐Lindberg, E., Larson, R. A., Lyons, R. M., Muus, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.7999 · Cited by 199
Self-citation
Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis
Ferrada, M. A., Savic, S., Cardona, D. O., Collins, J. C., Alessi, H. D., Gutierrez‐Rodrigues, F., Kumar, D. B. U., Wilson, L., Goodspeed, W. J., Topilow, J. S., et al. (2022) · Blood · doi:10.1182/blood.2022016985 · Cited by 199
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
Alessandrino, E. P., Porta, M. G. D., Bacigalupo, A. P., Lint, M. T. V., Falda, M., Onida, F., Bernardi, M., Iori, A. P., Rambaldi, A., Cerretti, R., et al. (2008) · Blood · doi:10.1182/blood-2008-03-143735 · Cited by 194
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM
Rosé, C., Bréchignac, S., Vassilief, D., Pascal, L. B., Stamatoullas, A., Guerci‐Bresler, A., Larbaa, D., Dreyfus, F., Beyne‐Rauzy, O., Chaury, M., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2009.12.004 · Cited by 197
Self-citation
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes
Mohamedali, A. M., Gäken, J. A., Twine, N. A., Ingram, W. A., Westwood, N., Lea, N. C., Hayden, J., Donaldson, N., Aul, C., Gattermann, N., et al. (2007) · Blood · doi:10.1182/blood-2007-03-079673 · Cited by 195
Self-citation
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes
Silverman, L. R., Fenaux, P., Mufti, G. J., Santini, V., Hellström‐Lindberg, E., Gattermann, N., Sanz, G. F., List, A. F., Gore, S. D., & Seymour, J. F. (2011) · Cancer · doi:10.1002/cncr.25774 · Cited by 194
Self-citation
Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies
Tiu, R. V., Gondek, L. P., O’Keefe, C. L., Elson, P. J., Huh, J., Mohamedali, A. M., Kulasekararaj, A. G., Advani, A. S., PAQUETTE, R. L., List, A. F., et al. (2011) · Blood · doi:10.1182/blood-2010-07-295857 · Cited by 197
Self-citation
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
Valent, P., Orazi, A., Steensma, D. P., Ebert, B. L., Haase, D. T., Malcovati, L., van de Loosdrecht, A. A., Haferlach, T., Westers, T. M., Wells, D. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19008 · Cited by 197
Self-citation
Myelodysplastic syndromes: Contemporary review and how we treat
Gangat, N., Patnaik, M. M., & Tefferi, A. (2015) · American Journal of Hematology · doi:10.1002/ajh.24253 · Cited by 200
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide
Sheng, W., Chen, X., Rocha, K., Epling‐Burnette, P. K., Djeu, J. Y., Liu, Q., Byrd, J. C., Sokol, L., Lawrence, N., Pireddu, R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811267106 · Cited by 195
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis
Thol, F. R., Weissinger, E. M., Krauter, J., Wagner, K., Damm, F., Wichmann, M., Göhring, G., Schumann, C., Bug, G., Ottmann, O. G., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.025494 · Cited by 195
Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions—A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group
Schroeder, T. A., Rachlis, E., Bug, G., Stelljes, M., Klein, S., Steckel, N. K., Wolf, D. G. F., Ringhoffer, M., Czibere, A. G., Nachtkamp, K., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.12.016 · Cited by 192
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
Steensma, D. P., Wermke, M., Klimek, V. M., Greenberg, P. L., Font, P., Komrokji, R. S., Yang, J., Brunner, A. M., Carraway, H. E., Adès, L., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01328-9 · Cited by 206
Self-citation
Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia
Tefferi, A., Mesa, R. A., Schroeder, G. S., Hanson, C. A., Li, C., & Dewald, G. W. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02796.x · Cited by 192
Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age
Deeg, H. J., Shulman, H. M., Anderson, J. E., Bryant, E. M., Gooley, T. A., Slattery, J. T., Anasetti, C., Fefer, A., Storb, R. F., & Appelbaum, F. R. (2000) · Blood · doi:10.1182/blood.v95.4.1188.004k38_1188_1194 · Cited by 190
Hypomethylation and up-regulation ofPD-1in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
Ørskov, A. D., Treppendahl, M. B., Skovbo, A., Holm, M. S., Friis, L. S., Hokland, M., & Grønbæk, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3324 · Cited by 190
Immunosuppressive Therapy for Patients With Myelodysplastic Syndrome: A Prospective Randomized Multicenter Phase III Trial Comparing Antithymocyte Globulin Plus Cyclosporine With Best Supportive Care—SAKK 33/99
Passweg, J. R., Giagounidis, A. A. N., Simcock, M., Aul, C., Dobbelstein, C. E., Stadler, M., Ossenkoppele, G. J., Hofmann, W., Schilling, K., Tichelli, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2686 · Cited by 189
Self-citation
Epidemiology and Etiology
Roos, A. J. D. (2013) · Springer eBooks · doi:10.1007/978-3-642-36229-3_2 · Cited by 190
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
Garcia‐Manero, G., Chien, K. S., & Bravo, G. M. (2020) · American Journal of Hematology · doi:10.1002/ajh.25950 · Cited by 192
Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome
Ogata, K. (2002) · Blood · doi:10.1182/blood-2002-01-0222 · Cited by 186
Familial myelodysplasia and acute myeloid leukaemia – a review
Owen, C., Barnett, M. J., & Fitzgibbon, J. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06909.x · Cited by 192

Authors: Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G., & Bennett, J.
Affiliations: Tokyo Medical University (JP)
From the Hematology Divisions of Stanford University Medical Center, Stanford, CA; the Rochester Medical Center, Rochester, NY; the University of Chicago, Chicago, IL; Centre Hospitalier Universitaire, Lille, France; Hospital La Fe, Valencia, Spain; Hospital Vall d'Hebron, Barcelona, Spain; the Royal Bournemouth Hospital, Bournemouth, UK; the Tokyo Medical College, Tokyo, Japan; the Heinrich Heine University, Dusseldorf, Germany; and the King's College Hospital, London, UK.
ORCID: Greenberg, Peter
Cox, Christopher
Fenaux, Pierre
Morel, Pierre
Sanz, Guillermo
Sanz, Miguel
Oscier, David
Ohyashiki, Kazuma
Toyama, Keisuke
Mufti, Ghulam
Bennett, John
Venue: Blood
Publisher: American Society of Hematology
Published: 1997-03-15
Volume: 89
Issue: 6
Pages: 2079-2088
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood.v89.6.2079
OpenAlex: W187238933
Cited by: 4,427
References: 33
Citations by year: 2026: 45 · 2025: 69 · 2024: 93 · 2023: 124 · 2022: 131 · 2021: 155 · 2020: 167 · 2019: 144 · 2018: 174 · 2017: 226 · 2016: 183 · 2015: 205 · 2014: 232 · 2013: 253 · 2012: 256
FWCI: 36.61
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Blood (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords: myelodysplastic syndrome, prognostic score, International Prognostic Scoring System, risk stratification, bone marrow cytogenetics, acute myeloid leukemia transformation, bone marrow blasts, cytopenia, survival, del(5q), del(20q)
MeSH terms: Acute Disease, Adolescent, Adult, Age Factors, Aged, Bone Marrow, Female, Follow-Up Studies, Humans, Leukemia, Myeloid, Male, Middle Aged, Myelodysplastic Syndromes, Prognosis, Sex Factors, Multivariate Analysis, Survival Analysis, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks